職位描述
醫(yī)藥銷(xiāo)售代表（該職位主要負(fù)責(zé)云南大理等周邊地區(qū)，有負(fù)責(zé)過(guò)三甲醫(yī)院銷(xiāo)售者優(yōu)先考慮）
主要職責(zé)：
1. 積極實(shí)施所轄醫(yī)院年、季、月度醫(yī)藥銷(xiāo)售計(jì)劃，合理分配和實(shí)施銷(xiāo)售費(fèi)用預(yù)算；
2. 配合落實(shí)市場(chǎng)部的推廣活動(dòng)，以及其他部門(mén)（質(zhì)量、財(cái)務(wù)和人力資源等）工作；
3. 新客戶(hù)開(kāi)發(fā)與上量維護(hù)；
4. 協(xié)助商務(wù)部做好銷(xiāo)售訂單、履行與管理工作；
5. 按時(shí)完成工作報(bào)告；
6. 學(xué)習(xí)產(chǎn)品知識(shí)和提高工作技能；
7. 完成上級(jí)交付的其他任務(wù)。
任職資格：
1. 醫(yī)學(xué)相關(guān)專(zhuān)業(yè)或經(jīng)濟(jì)、管理相關(guān)專(zhuān)業(yè)，大學(xué)專(zhuān)科以上學(xué)歷；
2. 2年及以上臨床醫(yī)藥銷(xiāo)售工作經(jīng)驗(yàn)（有骨科、風(fēng)濕科、皮科等臨床用藥推廣及銷(xiāo)售經(jīng)驗(yàn)佳）；
3. 通曉專(zhuān)業(yè)及業(yè)務(wù)知識(shí)，掌握公司所經(jīng)營(yíng)產(chǎn)品外行業(yè)動(dòng)態(tài)，掌握市場(chǎng)營(yíng)銷(xiāo)相關(guān)知識(shí)，了解公司所經(jīng)營(yíng)產(chǎn)品技術(shù)知識(shí)；
4. 熟練使用WORD,EXCEL，POWERPOINT等辦公軟件，具備網(wǎng)絡(luò)知識(shí)，講課能力；
5. 良好的英語(yǔ)應(yīng)用能力；
6. 人際能力、溝通能力、影響力、計(jì)劃與執(zhí)行能力、客戶(hù)服務(wù)能力。
企業(yè)簡(jiǎn)介
上海中信國(guó)健醫(yī)藥發(fā)展有限公司
上海中信國(guó)健醫(yī)藥發(fā)展有限公司為上海中信國(guó)健藥業(yè)股份有限公司全資子公司。
上海中信國(guó)健藥業(yè)股份有限公司（以下簡(jiǎn)稱(chēng)“中信國(guó)健”）是由中國(guó)中信集團(tuán)有限公司旗下中信泰富有限公司投資控股的生物醫(yī)藥高新技術(shù)企業(yè)。公司自2002年創(chuàng)建以來(lái)，專(zhuān)注于抗體藥物的研發(fā)、中試和產(chǎn)業(yè)化，現(xiàn)已發(fā)展成為國(guó)內(nèi)抗體制藥領(lǐng)域的領(lǐng)軍企業(yè)，提供覆蓋治療腫瘤、自身免疫性疾病、抗器官移植排斥反應(yīng)等重大疾病領(lǐng)域的靶向藥物。
作為一家以研發(fā)為基礎(chǔ)的生物制藥公司，中信國(guó)健已成功構(gòu)建了抗體藥物開(kāi)發(fā)和產(chǎn)業(yè)化平臺(tái)并掌握核心技術(shù)，具備持續(xù)開(kāi)發(fā)新藥的創(chuàng)新能力。公司生產(chǎn)規(guī)模位居行業(yè)前列。
Shanghai CP Guojian Pharmaceutical Co., Ltd. (CPGJ) is a high-tech bio -pharmaceutical company which is co-invested and led by China International Trust and Investment Corporation (CITIC) Group. CPGJ focuses on R&D, pilot development, industrialization and commercialization of monoclonal antibody drugs. Established in 2002 and going through more than ten years of growth, CPGJ has become a leading player in China’s domestic therapeutic Mab area. It has built up the largest production capacity for monoclonal antibody drugs in China and further expansion is undergoing within CPGJ’s strategic planning. The company’s product pipeline has covered the therapeutic solutions for critical diseases in Oncology, Transplantation and Autoimmune Disorders. Its drug for rheumatic disease has maintained a leading domestic market share in the biological anti-rheumatic drugs field in China.
Dedicated to sharpening its Research & Development capability, CPGJ has successfully produced key technological know-hows for the development and industrialization of monoclonal antibody drugs. As CPGJ’s wholly owned R&D organization, Biotechnology Institute of Shanghai CP Guojian focuses on discovery and early development of therapeutic antibodies and proteins, as well as innovation of technologies and processes to support drug development. The institute has established a comprehensive technological platform with a strong capability to take a drug development program from early discovery through CMC stage.
現(xiàn)由于公司發(fā)展需要，誠(chéng)聘具有創(chuàng)新精神和成就事業(yè)理想的優(yōu)秀人才加盟。
請(qǐng)符合條件的應(yīng)聘者將中英文簡(jiǎn)歷等信息發(fā)送E-mail至：cpgjhr@cpgj-pharm.com （請(qǐng)?jiān)卩]件題目上注明應(yīng)聘職位等信息）
[展開(kāi)全文]
[收縮全文]
